Technologies & Platforms

Start Your Project Now!

Please note: Our products and services are not intended to be used directly in diagnostic or therapeutic procedures.

Here's how you can reach us...

Tel:
Email:

GalNAc-Conjugated Delivery System Platforms

Inquiry

GalNAc-conjugated drug delivery platforms are key technologies for next-generation nucleic acid drug discovery due to their unique targeted and efficient delivery properties. CD Formulation is continuously developing and optimizing a wide range of GalNAc-conjugated systems to offer innovative therapeutic solutions for complex diseases.

Advantages of GalNAc-Conjugated Delivery System Platforms

GalNAc is a ligand for the asialoglycoprotein receptor (ASGPR), an endocytic receptor that is highly specifically expressed on the membrane surface of hepatocytes and almost not expressed in other cells. The ASGPR and clathrin-mediated endocytosis can effectively transport GalNAc from the cell surface to the cytoplasm. GalNAc conjugation has become the most advanced siRNA delivery technology, addressing three major challenges in nucleic acid drug development: poor targeting, severe off-target effects, and poor stability.

Fig.1 Advantages of GalNAc-Conjugated drug delivery platforms Fig.1 Features of GalNAc-Conjugated drug delivery platforms. (CD Formulation)

Our Capabilities of GalNAc-Conjugated Delivery System Platforms

Targeted Delivery - GalNAc technology can specifically target the hepatocyte receptor (ASGPR) in the liver for precise drug delivery.
Efficient Delivery - GalNAc conjugates are optimized for efficient drug delivery at low doses, reducing systemic toxicity and improving therapeutic efficacy.
Multiple Conjugations - The platform supports the loading of multiple drugs and biomolecules, including siRNAs, antisense oligonucleotides (ASOs), small molecule drugs, and more.

Types of GalNAc-conjugated Drug Delivery Platforms

CD Formulation is committed to providing robust technical support and solutions for biopharmaceutical research and drug discovery through innovative GalNAc-conjugated drug delivery platforms. Currently, the types of platforms we offer include the following.

Items	Descriptions	Applications
GalNAc-modified siRNA Platform	Enhances targeting and cellular uptake in hepatocytes, thereby improving the inhibition of anti-target gene expression.	Used to treat gene-related genetic diseases and tumors by precisely targeting and reducing the expression of specific genes.
GalNAc-modified mRNA Platform	Enhances mRNA uptake and translation efficiency in hepatocytes to ensure efficient protein expression.	Suitable for vaccine development and gene therapy, particularly in infectious disease and tumor immunotherapy.
GalNAc-modified Lipid Nanoparticles Platform	Combining GalNAc with lipid nanoparticles enhances drug stability and delivery efficiency while safeguarding nucleic acids from degradation.	Suitable for systemic drug delivery to enhance the biocompatibility and solubility of nucleic acid drugs.
GalNAc-modified DNA Platform	Enhance the efficacy of DNA drugs in target cells by increasing their uptake through GalNAc modification.	Used in gene editing and gene supplementation therapies to improve targeting.
Multiple Modification Platform	Combine GalNAc with other modifications (e.g., polyethylene glycol, PEG) to optimize drug delivery, enhance drug stability, and improve drug efficacy.	Suitable for the development of multiple nucleic acid drugs to enhance the potential for personalized therapy.

Highlights of GalNAc-conjugated Drug Delivery Platforms

Our platform is suitable for the design of various nucleic acid drugs, including siRNA and mRNA, enabling customized development according to different therapeutic needs.
GalNAc offers good biocompatibility, reducing immune responses and toxicity, ensuring the safety of clinical applications.
It is suitable for the treatment of various liver diseases, including but not limited to cirrhosis, fatty liver, liver cancer, and other metabolic liver diseases.
We provide comprehensive technical support and consultancy services from initial design and synthesis optimization to final evaluation.

Services Provided by the GalNAc-Conjugated Drug Delivery Platform

CD Formulation's GalNAc-Conjugated drug delivery system platform offers an advanced and precise solution for liver disease treatment through its efficient targeted delivery capabilities, versatility, and high specificity, greatly expanding the potential for nucleic acid drug development. Our platform enables customers to access customized and efficient drug development and formulation services.

Nucleic Acid-Conjugate Development Services

Our GalNAc-conjugate drug delivery platform provides a comprehensive solution in nucleic acid-conjugate development, including the development of conjugates for various types of nucleic acids. Through our one-stop service, we ensure that we meet our clients' specific needs from the initial project design to the final evaluation.

Publication Data

Technology: Delivering oligonucleotide drugs by GalNAc-based delivery platform

Journal: ACS omega

IF: 3.7

Published: 2021

Results:

Oligonucleotides (ONs) can selectively inhibit target genes through antisense and RNA interference mechanisms, making their potential therapeutic applications a topic of significant interest. The clinical application of oligonucleotides has overcome multiple barriers and has become one of the most active areas in the development of novel therapies. To achieve efficient and specific cellular uptake, connecting various functional groups to ONs has been a focal point of research over the past decade. Among these, the liver-targeting ligand N-acetylgalactosamine (GalNAc) has shown great promise and has been evaluated in several preclinical and clinical trials to improve cellular absorption of ONs and tissue-specific delivery. GalNAc-based delivery relies on the asialoglycoprotein receptor, which is highly expressed in liver hepatocytes and mediates the binding and uptake of circulating glycoproteins via receptor-mediated endocytosis. This review aims to outline the state of GalNAc-mediated liver-targeted delivery of small interfering RNA and antisense oligonucleotides, highlighting the substantial efforts and recent advancements in the development of GalNAc conjugate formulations.

Fig.2 GalNAc-mediated siRNA and ASO delivery to liver hepatocytes. (Cui H, et al., 2021)

CD Formulation, with our extensive experience and advanced technology platforms, is dedicated to providing innovative and efficient nucleic acid delivery solutions for our clients. Contact us, and we will expedite the development of your project.

References

Cui H, Zhu X, Li S, et al. Liver-targeted delivery of oligonucleotides with N-acetylgalactosamine conjugation. ACS omega. 2021, 6(25): 16259-16265.

How It Works

STEP 1

Submit a service request describing your specific research or development need.

STEP 2

We'll email you to provide your quote and confirm order details if applicable.

STEP 3

Execute the project with real-time communication, and deliver the final report promptly.

Related Services